Asking children (aged 12-17.9) to taste samples of healthy meals and provide feedback about taste, texture, and ideas for improvement

To evaluate the safety and effectiveness of the GPX® Embolic Device when used as indicated for embolization procedures, procedures to stop blood flow to certain tumors.

The purpose of this study is to develop and validate an Artificial intelligence (AI)-based tissue sample analysis tool that can predict response & progression rates to chemotherapy in intermediate-risk (IR) and high-risk (HR) Non-muscle invasive bladder cancer (NMIBC) patients. This study will use AI-based tissue sample analysis as a possible tool to help predict which patients are at high-risk for cancer recurrence and progression after surgery and chemotherapy treatment. Specimens will be obtained for each patient before treatment and at the 12, 24, & 36 month follow-up to be analyzed using the AI-based tool.

The goal of this study is to help CAPRICORN understand the needs of primary care clinics in North Carolina that provide free or low-cost healthcare. We will focus on how these clinics can offer cancer screening events to people in the community. To do this, we will create and use a survey to learn more about the needs of 3-4 clinics in North Carolina. Our findings will be shared in a report that includes suggestions for how CAPRICORN can grow over the next five years.

The aim of this study for low and standard risk germ cell tumor (GCT) patients is to minimize toxicity by reducing therapy while maintaining current survival rates. The trial will eliminate chemotherapy for low risk patients who are likely cured with surgery and will observe the salvage rates among those who recur.

We are surveying families of pediatric hematology/oncology patients to find out their interest in and use of integrative and complementary health practices.

The CMR is a population based breast imaging registry for women screened for breast cancer in NC.

The purpose of the study is to determine whether the continuing detection of cell-free plasma tumor DNA (ptDNA), circulating tumor cells (CTCs), and cytokines (chemicals that help the immune system communicate) in the blood can help to better evaluate the status of a patients cancer over the course of therapy.

This study aims to design and improve tools that can be used to select strategies for improving colorectal cancer screening in different settings and populations. Interviews, surveys, and focus groups will be conducted with individuals who make decisions related to colorectal cancer screening interventions about their understanding, preferences, and suggestions related to these tools and intervention strategies.

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occurs which may kill the cancer cell. Nivolumab is a medicine that may boost a patient's immune system. Giving nivolumab in combination with blinatumomab may cause the cancer to stop growing for a period of time, and for some patients, it may lessen the symptoms, such as pain, that are caused by the cancer.